Theracryf Plc
Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioural brain disorders. The company develops orexin-1 antagonist for the treatment of binge eating disorder and anxiety; and atypical dopamine transporter inhibitor (DAT) to treat fatigue and narcolepsy. It also develops SFX-01 for the treatment of brain cancer glioblastoma and n… Read more
Theracryf Plc (TCF) - Net Assets
Latest net assets as of September 2025: GBX4.80 Million GBX
Based on the latest financial reports, Theracryf Plc (TCF) has net assets worth GBX4.80 Million GBX as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX6.62 Million) and total liabilities (GBX1.82 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX4.80 Million |
| % of Total Assets | 72.56% |
| Annual Growth Rate | 4.4% |
| 5-Year Change | -49.46% |
| 10-Year Change | N/A |
| Growth Volatility | 90.98 |
Theracryf Plc - Net Assets Trend (2017–2025)
This chart illustrates how Theracryf Plc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Theracryf Plc (2017–2025)
The table below shows the annual net assets of Theracryf Plc from 2017 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | GBX5.97 Million | +154.98% |
| 2024-03-31 | GBX2.34 Million | -56.17% |
| 2023-03-31 | GBX5.34 Million | -42.12% |
| 2022-03-31 | GBX9.23 Million | -21.88% |
| 2021-03-31 | GBX11.81 Million | +180.95% |
| 2020-03-31 | GBX4.20 Million | +102.50% |
| 2019-03-31 | GBX2.08 Million | -46.37% |
| 2018-03-31 | GBX3.87 Million | -8.44% |
| 2017-03-31 | GBX4.23 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Theracryf Plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2250600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | GBX5.32 Million | 89.19% |
| Other Comprehensive Income | GBX2.38 Million | 39.91% |
| Other Components | GBX28.70 Million | 480.73% |
| Total Equity | GBX5.97 Million | 100.00% |
Theracryf Plc Competitors by Market Cap
The table below lists competitors of Theracryf Plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Reem Capital Corp.
V:REEM-P
|
$537.29 |
|
Neovacs S.A.
PA:ALNEV
|
$537.87 |
|
Biztech Konsulting SA
WAR:BTK
|
$539.04 |
|
Restart Life Sciences Corp.
PINK:NMLSD
|
$539.72 |
|
Intermarket Sec.
KAR:IMS
|
$535.18 |
|
CANADA ZINC METALS
MU:M9R
|
$535.00 |
|
Mahanna Islamic Inde
KAR:MIIETF
|
$534.39 |
|
SOLOMON SYSTECH
MU:RZF
|
$533.86 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Theracryf Plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,341,000 to 5,969,000, a change of 3,628,000 (155.0%).
- Net loss of 1,941,000 reduced equity.
- New share issuances of 5,152,000 increased equity.
- Other comprehensive income decreased equity by 320,000.
- Other factors increased equity by 737,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX-1.94 Million | -32.52% |
| Share Issuances | GBX5.15 Million | +86.31% |
| Other Comprehensive Income | GBX-320.00K | -5.36% |
| Other Changes | GBX737.00K | +12.35% |
| Total Change | GBX- | 154.98% |
Book Value vs Market Value Analysis
This analysis compares Theracryf Plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 18.49x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 3.60x to 18.49x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-03-31 | GBX0.06 | GBX0.21 | x |
| 2018-03-31 | GBX0.05 | GBX0.21 | x |
| 2019-03-31 | GBX0.02 | GBX0.21 | x |
| 2020-03-31 | GBX0.03 | GBX0.21 | x |
| 2021-03-31 | GBX0.08 | GBX0.21 | x |
| 2022-03-31 | GBX0.03 | GBX0.21 | x |
| 2023-03-31 | GBX0.02 | GBX0.21 | x |
| 2024-03-31 | GBX0.01 | GBX0.21 | x |
| 2025-03-31 | GBX0.01 | GBX0.21 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Theracryf Plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -32.52%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.28x
- Recent ROE (-32.52%) is above the historical average (-69.41%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -72.56% | 0.00% | 0.00x | 1.12x | GBX-3.49 Million |
| 2018 | -66.73% | 0.00% | 0.00x | 1.10x | GBX-2.97 Million |
| 2019 | -126.40% | 0.00% | 0.00x | 1.33x | GBX-2.83 Million |
| 2020 | -64.58% | 0.00% | 0.00x | 1.16x | GBX-3.14 Million |
| 2021 | -22.64% | -1378.35% | 0.02x | 1.05x | GBX-3.86 Million |
| 2022 | -29.59% | 0.00% | 0.00x | 1.04x | GBX-3.65 Million |
| 2023 | -75.70% | -914.71% | 0.07x | 1.16x | GBX-4.58 Million |
| 2024 | -134.00% | -792.17% | 0.13x | 1.31x | GBX-3.37 Million |
| 2025 | -32.52% | 0.00% | 0.00x | 1.28x | GBX-2.54 Million |
Industry Comparison
This section compares Theracryf Plc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $10,807,025
- Average return on equity (ROE) among peers: -134.93%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Theracryf Plc (TCF) | GBX4.80 Million | -72.56% | 0.38x | $536.01 |
| 4BASEBIO UK SOCIETAS (4BB) | $11.70 Million | -27.66% | 0.26x | $10.53K |
| Aptamer Group PLC (APTA) | $8.05 Million | -26.00% | 0.43x | $3.12K |
| Arecor Therapeutics PLC (AREC) | $773.79K | -355.70% | 4.54x | $3.33K |
| Bioventix (BVXP) | $4.20 Million | 36.18% | 0.07x | $9.85K |
| Cizzle Biotechnology Holdings PLC (CIZ) | $741.00K | -0.02% | 3.16x | $747.56 |
| Fusion Antibodies PLC (FAB) | $1.46 Million | 79.21% | 0.28x | $2.07K |
| Faron Pharmaceuticals Oy (FARN) | $1.61 Million | -823.73% | 5.34x | $27.00K |
| Futura Medical (FUM) | $9.72 Million | -50.98% | 0.21x | $424.60 |
| hVIVO plc (HVO) | $2.86 Million | -195.31% | 2.17x | $5.18K |
| International Biotechnology Trust plc (IBT) | $66.95 Million | 14.71% | 0.00x | $1.10K |